May 30, 2006 -- CollaGenex received FDA approval for Oracea, a once-daily oral drug for rosacea; SenoRx, which makes minimally invasive breast cancer products, filed for its IPO; Vical said its partner AnGes will provide up to $100 million in funding for the Phase III clinical trials of cancer drug Allovectin-7R; Biogen Idec released positive data from a trial of a new multiple sclerosis drug; Samaritan Pharma reported the results from a Phase II test of its HIV therapy; ViaCell said the Patent Office had rejected patents held by PharmaStem Therapeutics, which were the subject of a suit between the companies; Applied Biosystems joined with MDS Sciex to announce LightSight, a software product that identifies metabolites; Applied Biosystems also announced that it paid $120 million in cash to buy Agencourt Personal Genomics; CuraGen began a Phase II test of velafermin as a therapy for oral mucositis; and ISTA Pharma will begin two Phase III trials of its once-daily formulation of Xibrom. The Centient Biotech 200™ fell 55.5 points to 3648.45, a loss of 1.50%. More details...
